SecBot SecBot
EFFECT ·Filed Mar 31, 2026

INM

InMed Pharmaceuticals Inc.
BEARISH
Impact 7/10
Horizondays Processed7mo ago SEC9999999995-26-000999
IPO/offering going effective
Actionable Insight ▼ Bearish

Monitor for imminent takedown of shares under this shelf; any offering will be highly dilutive given current market cap. Downward pressure on share price is likely upon announcement of any issuance.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.6450
T+0 close · Mar 31, 2026 · via day close
Latest settled
+138.76%
T+60 · $1.54
Vs SPY
+126.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 31 $0.6450entry
  2. T+1 · 8mo ago +3.88%α +3.13% · $0.6700
  3. T+5 · 7mo ago +0.31%α −3.63% · $0.6470
  4. T+20 · 7mo ago +8.68%α −0.74% · $0.7010
  5. T+60 · 5mo ago +138.76%α +126.38% · $1.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals' S-3 shelf registration has become effective, allowing the company to raise up to $50 million through future offerings of common shares, preferred shares, warrants, or other securities. Given the company's $2 million market cap and existing going concern doubts, this creates a significant dilution overhang.

Key Facts

  • S-3 shelf registration became effective on March 30, 2026
  • Company may raise up to $50 million in aggregate value over time
  • Offering can include common stock, preferred stock, warrants, subscription rights, or units
  • Market cap is only $2 million, implying potential for extreme dilution
  • Company faces substantial doubt about going concern due to operating losses and adverse U.S. legislation impacting BayMedica

Financial Impact

Up to $50 million in potential dilution against a $2 million market cap

dilutionequity valueshare price

Risk Factors

  • Extreme shareholder dilution due to large shelf size relative to market cap
  • Equity issuances could further depress share price in a low-liquidity environment
  • Ongoing going concern risks exacerbated by reliance on capital markets for survival

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-000999
Document: 9999999995-26-000999-index.html9999999995-26-000999
Document: 9999999995-26-000999.txt9999999995-26-000999

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 31, 2026